Product image of Ethinylestradiol/Levonorgestrel Teva (Ethinylestradiol, Levonorgestrel) supplied by GNH India

Ethinylestradiol/Levonorgestrel Teva

Active Ingredient:
Ethinylestradiol, Levonorgestrel
Origin:
EU

Ethinylestradiol/Levonorgestrel Teva (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol/Levonorgestrel Teva is a prescription combined oral contraceptive that contains the synthetic estrogen ethinylestradiol and the progestogen levonorgestrel. It is marketed in the European Union and supplied as an oral tablet, though specific strength information is not disclosed here. The product works by preventing ovulation and creating cervical and endometrial conditions unfavorable for fertilisation. It is intended for use by women seeking birth control and is classified under hormonal contraceptives.

Manufacturer / TM Owner

Teva Nederland B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ethinylestradiol/Levonorgestrel Teva is indicated for hormonal contraception in women of reproductive age.

  • Prevention of pregnancy when taken as directed in a cyclic regimen.
  • Regulation of menstrual cycles and reduction of dysmenorrhea.
  • Management of acne associated with androgen excess.
  • Decrease in the risk of ovarian cyst formation.
  • Potential benefit in reducing the incidence of endometrial hyperplasia.

Side Effects

Side effects of Ethinylestradiol/Levonorgestrel Teva vary in frequency and severity; most are mild and transient, while rare events may require medical attention.

Common

  • Nausea or mild gastrointestinal upset.
  • Breast tenderness.
  • Spotting or breakthrough bleeding.
  • Mood changes such as irritability.

Serious

  • Deep vein thrombosis or pulmonary embolism.
  • Stroke or transient ischemic attack.
  • Severe allergic reaction with rash or swelling.

Precautions & Warnings

Before prescribing Ethinylestradiol/Levonorgestrel Teva, clinicians should evaluate individual risk factors and counsel patients on appropriate use.

  • Not for use during pregnancy; contraindicated in women with known or suspected pregnancy (Category X).
  • Avoid in patients with a history of thromboembolic disorders, stroke, or myocardial infarction.
  • Use with caution in smokers aged 35 years or older.
  • Screen for hypertension, diabetes, or liver disease before initiation.
  • Discuss potential interactions with other hormonal medications.
  • Advise against use in women with estrogen‑dependent tumors.
  • Ensure regular follow‑up to monitor blood pressure and menstrual changes.

Avoid Interactions

Ethinylestradiol/Levonorgestrel Teva can interact with several medicines, affecting efficacy or safety.

Avoid

  • Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin) that reduce contraceptive effectiveness.
  • Rifampin or other potent CYP3A4 inducers.
  • Certain antiretroviral agents (e.g., efavirenz) that lower hormone levels.

Use with caution

  • Antifungal azoles (e.g., ketoconazole) that may increase hormone concentrations.
  • St. John’s wort, a mild CYP3A4 inducer.
  • Selective serotonin reuptake inhibitors (SSRIs) that can affect bleeding patterns.

Frequently Asked Questions

The combination suppresses ovulation by inhibiting the mid‑cycle surge of luteinising hormone (LH) and follicle‑stimulating hormone (FSH) and also alters cervical mucus and the endometrial lining to reduce the chance of fertilisation and implantation.

It is usually taken once daily at the same time each day for 21 consecutive days followed by a 7‑day hormone‑free interval; missed tablets should be taken as soon as remembered according to the product’s missed‑dose guidelines.

Smoking, especially in women aged 35 years or older, increases the risk of serious cardiovascular events with combined oral contraceptives, so clinicians advise caution or alternative methods for this group.

Commonly reported effects include mild nausea, breast tenderness, spotting or breakthrough bleeding between periods, and occasional mood changes such as irritability.

The product should be discontinued if pregnancy is confirmed, if a serious adverse event occurs, or if a healthcare provider determines that the risks outweigh the benefits.

Combined oral contraceptives are generally not recommended during the first six weeks postpartum while breastfeeding, because estrogen may reduce milk production; a progestogen‑only method is often preferred.

Most antibiotics do not affect the efficacy of combined oral contraceptives, but enzyme‑inducing agents such as rifampin can lower hormone levels and increase the risk of unintended pregnancy.

Weight changes reported with combined oral contraceptives are usually modest and may be related to fluid retention rather than true fat gain; individual responses vary.

Take the missed tablet as soon as remembered, then continue with the next scheduled dose; if two or more consecutive pills are missed, additional contraceptive protection may be needed for a short period.

No, combined oral contraceptives do not provide protection against STIs; barrier methods such as condoms should be used for STI prevention.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ethinylestradiol, Levonorgestrel

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT